BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33389409)

  • 21. Diffuse distribution of tumor-infiltrating lymphocytes is a marker for better prognosis and chemotherapeutic effect in triple-negative breast cancer.
    Hida AI; Watanabe T; Sagara Y; Kashiwaba M; Sagara Y; Aogi K; Ohi Y; Tanimoto A
    Breast Cancer Res Treat; 2019 Nov; 178(2):283-294. PubMed ID: 31402409
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple-negative breast cancer has worse overall survival and cause-specific survival than non-triple-negative breast cancer.
    Li X; Yang J; Peng L; Sahin AA; Huo L; Ward KC; O'Regan R; Torres MA; Meisel JL
    Breast Cancer Res Treat; 2017 Jan; 161(2):279-287. PubMed ID: 27888421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast conserving surgery (BCS) with adjuvant radiation therapy showed improved prognosis compared with mastectomy for early staged triple negative breast cancer patients Running title: BCS had better prognosis than mastectomy for early TNBC patients.
    Wang SE; Sun YD; Zhao SJ; Wei F; Yang G
    Math Biosci Eng; 2019 Sep; 17(1):92-104. PubMed ID: 31731341
    [No Abstract]   [Full Text] [Related]  

  • 24. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns.
    Tzikas AK; Nemes S; Linderholm BK
    Breast Cancer Res Treat; 2020 Aug; 182(3):643-654. PubMed ID: 32524352
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-negative breast cancer: An institutional analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK
    Indian J Cancer; 2014; 51(2):163-6. PubMed ID: 25104201
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of molecular subtype on breast cancer recurrence in young women treated with contemporary adjuvant therapy.
    Alabdulkareem H; Pinchinat T; Khan S; Landers A; Christos P; Simmons R; Moo TA
    Breast J; 2018 Mar; 24(2):148-153. PubMed ID: 28707744
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer.
    Ren YX; Hao S; Jin X; Ye FG; Gong Y; Jiang YZ; Shao ZM
    Breast; 2019 Feb; 43():97-104. PubMed ID: 30529406
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY.
    Tečić Vuger A; Šeparović R; Vazdar L; Pavlović M; Lepetić P; Šitić S; Bajić Ž; Šarčević B; Vrbanec D
    Acta Clin Croat; 2020 Mar; 59(1):97-108. PubMed ID: 32724280
    [TBL] [Abstract][Full Text] [Related]  

  • 29. T-bet
    Mori H; Kubo M; Kai M; Yamada M; Kurata K; Kawaji H; Kaneshiro K; Osako T; Nishimura R; Arima N; Okido M; Kishimoto J; Oda Y; Nakamura M
    Breast Cancer Res Treat; 2019 Aug; 176(3):569-577. PubMed ID: 31069590
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nottingham Prognostic Index is an Applicable Prognostic Tool in Non-Metastatic Triple-Negative Breast Cancer.
    Al jarroudi O; Zaimi A; Brahmi SA; Afqir S
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):59-63. PubMed ID: 30678381
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
    Wu SY; Tan Y; Guan YS
    Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-negative breast cancer survival prediction using artificial intelligence through integrated analysis of tertiary lymphoid structures and tumor budding.
    Hou X; Li X; Han Y; Xu H; Xie Y; Zhou T; Xue T; Qian X; Li J; Wang HC; Yan J; Guo X; Liu Y; Liu J
    Cancer; 2024 Apr; 130(S8):1499-1512. PubMed ID: 38422056
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.
    Bonsang-Kitzis H; Chaltier L; Belin L; Savignoni A; Rouzier R; Sablin MP; Lerebours F; Bidard FC; Cottu P; Sastre-Garau X; Laé M; Pierga JY; Reyal F
    PLoS One; 2015; 10(12):e0144359. PubMed ID: 26684197
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Body Mass Index and Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer.
    Floris G; Richard F; Hamy AS; Jongen L; Wildiers H; Ardui J; Punie K; Smeets A; Berteloot P; Vergote I; De Croze D; Meseure D; Salomon A; Laé M; Reyal F; Biganzoli E; Neven P; Desmedt C
    J Natl Cancer Inst; 2021 Feb; 113(2):146-153. PubMed ID: 33152071
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognosis in triple-negative apocrine carcinomas of the breast: A population-based study.
    Wu W; Wu M; Peng G; Shi D; Zhang J
    Cancer Med; 2019 Dec; 8(18):7523-7531. PubMed ID: 31642210
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial.
    Sharma P; Barlow WE; Godwin AK; Parkes EE; Knight LA; Walker SM; Kennedy RD; Harkin DP; Logan GE; Steele CJ; Lambe SM; Badve S; Gökmen-Polar Y; Pathak HB; Isakova K; Linden HM; Porter P; Pusztai L; Thompson AM; Tripathy D; Hortobagyi GN; Hayes DF
    J Clin Oncol; 2019 Dec; 37(36):3484-3492. PubMed ID: 31657982
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil-to-lymphocyte ratio as a predictor of survival in patients with triple-negative breast cancer.
    Patel DA; Xi J; Luo J; Hassan B; Thomas S; Ma CX; Campian JL
    Breast Cancer Res Treat; 2019 Apr; 174(2):443-452. PubMed ID: 30604000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparisons of Oncologic Outcomes between Triple-Negative Breast Cancer (TNBC) and Non-TNBC among Patients Treated with Breast-Conserving Therapy.
    Kim S; Park HS; Kim JY; Ryu J; Park S; Kim SI
    Yonsei Med J; 2016 Sep; 57(5):1192-8. PubMed ID: 27401651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.
    Dieci MV; Mathieu MC; Guarneri V; Conte P; Delaloge S; Andre F; Goubar A
    Ann Oncol; 2015 Aug; 26(8):1698-704. PubMed ID: 25995301
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive factors and patterns of recurrence in patients with triple negative breast cancer.
    Steward L; Conant L; Gao F; Margenthaler JA
    Ann Surg Oncol; 2014 Jul; 21(7):2165-71. PubMed ID: 24558065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.